Artelo Biosciences Inc. [NASDAQ: ARTL] slipped around -0.13 points on Thursday, while shares priced at $0.65 at the close of the session, down -16.05%. The company report on October 15, 2020 that Artelo Biosciences, Inc. Announces Closing of $7.6 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option.
Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate endogenous signaling pathways, including the endocannabinoid system, today announced the closing of an underwritten public offering of units for gross proceeds of approximately $7.6 million, which includes the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Artelo Biosciences, Inc. The offering is comprised of units, priced at a public offering price of $0.75 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $0.75 per share that expires on the fifth anniversary of the date of issuance. The securities comprising the units are immediately separable and were issued separately.
Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager.
Artelo Biosciences Inc. stock is now -75.81% down from its year-to-date (YTD) trading value. ARTL Stock saw the intraday high of $0.6579 and lowest of $0.59 per share. The company’s 52-week high price is 4.42, which means current price is +10.68% above from all time high which was touched on 02/03/20.
Compared to the average trading volume of 976.83K shares, ARTL reached a trading volume of 10086839 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Artelo Biosciences Inc. [ARTL]?
The Average True Range (ATR) for Artelo Biosciences Inc. is set at 0.16 The Price to Book ratio for the last quarter was 0.70, with the Price to Cash per share for the same quarter was set at 0.27.
How has ARTL stock performed recently?
Artelo Biosciences Inc. [ARTL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -28.24. With this latest performance, ARTL shares dropped by -27.28% in over the last four-week period, additionally sinking by -43.71% over the last 6 months – not to mention a drop of -73.35% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ARTL stock in for the last two-week period is set at 36.00, with the RSI for the last a single of trading hit 31.11, and the three-weeks RSI is set at 39.08 for Artelo Biosciences Inc. [ARTL]. The present Moving Average for the last 50 days of trading for this stock 0.9397, while it was recorded at 0.7787 for the last single week of trading, and 1.2869 for the last 200 days.
Artelo Biosciences Inc. [ARTL]: Deeper insight into the fundamentals
Return on Total Capital for ARTL is now -120.52, given the latest momentum, and Return on Invested Capital for the company is -81.57. Return on Equity for this stock declined to -81.57, with Return on Assets sitting at -63.15.
Reflecting on the efficiency of the workforce at the company, Artelo Biosciences Inc. [ARTL] managed to generate an average of -$543,044 per employee.Artelo Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.40 and a Current Ratio set at 5.40.
Earnings analysis for Artelo Biosciences Inc. [ARTL]
With the latest financial reports released by the company, Artelo Biosciences Inc. posted -0.17/share EPS, while the average EPS was predicted by analysts to be reported at -0.42/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 59.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ARTL.
Insider trade positions for Artelo Biosciences Inc. [ARTL]
There are presently around $0 million, or 0.30% of ARTL stock, in the hands of institutional investors. The top three institutional holders of ARTL stocks are: GOLDMAN SACHS GROUP INC with ownership of 14,223, which is approximately 0% of the company’s market cap and around 7.10% of the total institutional ownership; TOWER RESEARCH CAPITAL LLC (TRC), holding 700 shares of the stock with an approximate value of $0.0 in ARTL stocks shares; and WELLS FARGO & COMPANY/MN, currently with $0.0 in ARTL stock with ownership of nearly 6.25% of the company’s market capitalization.
Positions in Artelo Biosciences Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 2 institutional holders increased their position in Artelo Biosciences Inc. [NASDAQ:ARTL] by around 701 shares. Additionally, 1 investors decreased positions by around 799 shares, while 1 investors held positions by with 13,440 shares. The mentioned changes placed institutional holdings at 14,940 shares, according to the latest SEC report filing. ARTL stock had 1 new institutional investments in for a total of 700 shares, while 1 institutional investors sold positions of 799 shares during the same period.